Sonnet BioTherapeutics Holdings, Inc. (SONN) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-12-04

Sonnet BioTherapeutics Holdings, Inc. (SONN) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every SONN SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Sonnet BioTherapeutics Holdings, Inc. (SONN)

SEC CIK	0001106838

Recent SONN Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-12-02	Kenney Richard T	Chief Medical Officer	F — Tax withholding / forfeiture	16.9K	—	—	SEC
2025-12-02	Kenney Richard T	Chief Medical Officer	D — Derivative transaction	163.8K	—	—	SEC
2025-12-02	Kenney Richard T	Chief Medical Officer	D — Derivative transaction	9.4K	—	—	SEC
2025-12-02	Kenney Richard T	Chief Medical Officer	M — Option exercise	86.5K	—	—	SEC
2025-12-02	Kenney Richard T	Chief Medical Officer	D — Derivative transaction	69.6K	—	—	SEC
2025-12-02	Kenney Richard T	Chief Medical Officer	M — Option exercise	163.8K	—	—	SEC
2025-12-02	Bhatt Nailesh	Director	D — Derivative transaction	10.5K	—	—	SEC
2025-12-02	MCANDREW STEPHEN J	Chief Business Officer	D — Derivative transaction	6.4K	—	—	SEC
2025-12-02	Griffith Donald J.	Chief Financial Officer	D — Derivative transaction	10.4K	—	—	SEC
2025-12-02	McNeill Lori	Director	D — Derivative transaction	4.4K	—	—	SEC
2025-12-02	Dexter Susan	Director	D — Derivative transaction	9.6K	—	—	SEC
2025-12-02	Dyrness Albert D.	Director	D — Derivative transaction	4.5K	—	—	SEC
2025-12-02	Rao Raghu	Chief Executive Officer	D — Derivative transaction	22.4K	—	—	SEC
2025-12-02	Cini John K.	Director	D — Derivative transaction	14.1K	—	—	SEC
2025-07-11	Rao Raghu	Interim CEO	A — Grant or award	20.0K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Sonnet BioTherapeutics Holdings, Inc. (SONN). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2025-12-04 — Kenney Richard T (Chief Medical Officer)
2025-12-04 — MCANDREW STEPHEN J (Chief Business Officer)
2025-12-04 — Griffith Donald J. (Chief Financial Officer)
2025-12-04 — McNeill Lori (Director)
2025-12-04 — Dexter Susan (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SONN insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

SONN Insider Trading — FAQ

What is the latest insider trade for SONN?: Sonnet BioTherapeutics Holdings, Inc. (SONN) had 0 insider filings in the last 90 days, with the most recent on 2025-12-04. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying SONN stock?: 0 insider purchases of SONN were filed in the last 90 days.
How many insiders are selling SONN stock?: 0 insider sales of SONN were filed in the last 90 days.
Where can I see SONN SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every SONN SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live SONN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.